G W de Valk-de Roo - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Filters

G W de Valk-de Roo

Showing results (1-10 of 10) with videos related to

Pageof 1

Sort By:

Menopause (New York, N.Y.)|June 22, 1999

Raloxifene lowers serum lipoprotein(A) in healthy postmenopausal women: a randomized, double-blind, placebo-controlled comparison with conjugated equine estrogensV Mijatovic, M J van der Mooren, P Kenemans, et al.

Thrombosis and Haemostasis|January 12, 2001

Unopposed estrogen increases total plasma factor VII, but not active factor VII--a short-term placebo-controlled study in healthy postmenopausal womenG W de Valk-de Roo, C D Stehouwer, J J Emeis, et al.

Fertility and Sterility|December 16, 1998

Randomized, double-blind, placebo-controlled study of the effects of raloxifene and conjugated equine estrogen on plasma homocysteine levels in healthy postmenopausal womenV Mijatovic, C Netelenbos, M J van der Mooren, et al.

Clinical Endocrinology|August 6, 1999

Oestrogen has no short-term effect on intestinal strontium absorption in healthy postmenopausal womenM ten Bolscher, G W de Valk-de Roo, R Barto, et al.

Journal of Internal Medicine|June 26, 2003

Raloxifene, conjugated oestrogen and endothelial function in postmenopausal womenE J J Duschek, C D A Stehouwer, G W de Valk-de Roo, et al.

Arteriosclerosis, Thrombosis, and Vascular Biology|December 11, 1999

Both raloxifene and estrogen reduce major cardiovascular risk factors in healthy postmenopausal women: A 2-year, placebo-controlled studyG W de Valk-de Roo, C D Stehouwer, P Meijer, et al.

Clinical Chemistry|August 3, 1999

Plasma homocysteine is weakly correlated with plasma endothelin and von Willebrand factor but not with endothelium-dependent vasodilatation in healthy postmenopausal womenG W de Valk-de Roo, C D Stehouwer, J Lambert, et al.

Physiological Measurement|December 24, 1998

Extra-cellular volume estimation by electrical impedance--phase measurement or curve fitting: a comparative studyH G Goovaerts, T J Faes, G W de Valk-de Roo, et al.

Annals of the New York Academy of Sciences|June 18, 1999

Estimation of extracellular volume by a two-frequency measurementH G Goovaerts, T J Faes, G W de Valk-de Roo, et al.

Maturitas|April 2, 1998

Continuously combined hormone replacement therapy and bone turnover: the influence of dydrogesterone dose, smoking and initial degree of bone turnoverG W de Valk-de Roo, J C Netelenbos, I R Peters-Muller, et al.

Pageof 1

Search research articles

Showing results (1-10 of 10) with videos related to

Sort By:

Pageof 1

Menopause (New York, N.Y.)|June 22, 1999

Raloxifene lowers serum lipoprotein(A) in healthy postmenopausal women: a randomized, double-blind, placebo-controlled comparison with conjugated equine estrogensV Mijatovic, M J van der Mooren, P Kenemans, et al.

Thrombosis and Haemostasis|January 12, 2001

Unopposed estrogen increases total plasma factor VII, but not active factor VII--a short-term placebo-controlled study in healthy postmenopausal womenG W de Valk-de Roo, C D Stehouwer, J J Emeis, et al.

Fertility and Sterility|December 16, 1998

Randomized, double-blind, placebo-controlled study of the effects of raloxifene and conjugated equine estrogen on plasma homocysteine levels in healthy postmenopausal womenV Mijatovic, C Netelenbos, M J van der Mooren, et al.

Clinical Endocrinology|August 6, 1999

Oestrogen has no short-term effect on intestinal strontium absorption in healthy postmenopausal womenM ten Bolscher, G W de Valk-de Roo, R Barto, et al.

Journal of Internal Medicine|June 26, 2003

Raloxifene, conjugated oestrogen and endothelial function in postmenopausal womenE J J Duschek, C D A Stehouwer, G W de Valk-de Roo, et al.

Arteriosclerosis, Thrombosis, and Vascular Biology|December 11, 1999

Both raloxifene and estrogen reduce major cardiovascular risk factors in healthy postmenopausal women: A 2-year, placebo-controlled studyG W de Valk-de Roo, C D Stehouwer, P Meijer, et al.

Clinical Chemistry|August 3, 1999

Plasma homocysteine is weakly correlated with plasma endothelin and von Willebrand factor but not with endothelium-dependent vasodilatation in healthy postmenopausal womenG W de Valk-de Roo, C D Stehouwer, J Lambert, et al.

Physiological Measurement|December 24, 1998

Extra-cellular volume estimation by electrical impedance--phase measurement or curve fitting: a comparative studyH G Goovaerts, T J Faes, G W de Valk-de Roo, et al.

Annals of the New York Academy of Sciences|June 18, 1999

Estimation of extracellular volume by a two-frequency measurementH G Goovaerts, T J Faes, G W de Valk-de Roo, et al.

Maturitas|April 2, 1998

Continuously combined hormone replacement therapy and bone turnover: the influence of dydrogesterone dose, smoking and initial degree of bone turnoverG W de Valk-de Roo, J C Netelenbos, I R Peters-Muller, et al.

Pageof 1